Steatocystoma Multiplex Suppurativa Treated Successfully with Adalimumab and Topical Tofacitinib
Main Article Content
Keywords
Steatocystoma multiplex suppurativa, anti-TNF-alpha therapy, adalimumab, tofacitnib, anti-JAK
Abstract
Steatocystoma multiplex (SM) is a rare chronic dermatologic condition which may cause significant distress and negatively impact quality of life. Currently, there is no consensus for treatment. When inflammatory, it is called steatocystoma multiplex suppurativa, an even more rare condition that has shown reported success with anti-TNF-alpha therapy. We describe a patient case wherein adalimumab prescribed for autoimmune arthritis resulted in SMS remission, further supported with evidence of sustained remission with topical tofacitinib. This patient case supports other evidence showing adalimumab as a treatment option for SMS and highlights the potential of tofacitinib as a novel treatment.
References
2. Georgakopoulos JR, Ighani A, Yeung J. Numerous asymptomatic dermal cysts: Diagnosis and treatment of steatocystoma multiplex. Can Fam Physician. Dec 2018;64(12):892-899.
3. Fletcher J, Posso-De Los Rios C, Jambrosic J, Alavi A. Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex: Is It a New Variant of Hidradenitis Suppurativa? J Cutan Med Surg. Nov-Dec 2021;25(6):586-590. doi:10.1177/12034754211010145
4. Atzori L, Zanniello R, Pilloni L, Rongioletti F. Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab. J Eur Acad Dermatol Venereol. Oct 2019;33 Suppl 6:42-44. doi:10.1111/jdv.15848
5. Lowe MM, Naik HB, Clancy S, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. JCI Insight. Oct 2 2020;5(19)doi:10.1172/jci.insight.139932
6. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.